Skip to main content
. 2016 Jun 27;8(25):40152–40168. doi: 10.18632/oncotarget.10308

Figure 4. Olaparib sensitivity is enhanced by non-functional HR combined with defects in another DNA repair pathway.

Figure 4

A. siRNAs efficacy against MLH1, ERCC8, and MRE11A in combination, in OV1369(R2) cells was verified by Western blots. B. Olaparib sensitivity curves of OV1369(R2) representing non-treated cells, control siRNA (siScr), and single and double siRNAs against MRE11A and MLH1 together. C. IC50 representations of single and double siRNAs in resistant (dark grey bars), and intermediate (light grey bars) cells. Bars represent average ± SEM of IC50 values obtained by clonogenic assay. * denotes p < 0.05, ** p < 0.01, *** p < 0.001, ns = non-significant.